Summary of Cerus Corporation (NASDAQ:CERS) Ratings

June 29, 2018 - By Nicole Mills

During 2018 Q1 the big money sentiment increased to 1.84. That’s change of 0.39, from 2017Q4’s 1.45. 5 investors sold all, 27 reduced holdings as Cerus Corporation ratio is positive. 38 grew positions while 21 funds bought positions. Funds hold 69.09 million shares thus 17.19% more from 2017Q4’s 58.96 million shares.
18,970 were reported by Budros Ruhlin Roe. Sg Americas Securities Ltd Co has 13,206 shs. Steinberg Global Asset Mngmt holds 89,200 shs. State Bank Of New York Mellon Corporation owns 544,154 shs. Voya Inv Ltd Liability Com stated it has 52,929 shs or 0% of all its holdings. Northern Tru owns 1.46 million shs or 0% of their US capital. Goldman Sachs, a New York-based fund reported 178,551 shs. Manufacturers Life Insur Com The has 96,089 shs for 0% of their capital. Macquarie Grp Ltd holds 0% or 179,899 shs in its capital. Group One Trading L P stated it has 74,568 shs. Parametric Assoc Limited Com has 0% invested in Cerus Corporation (NASDAQ:CERS). Susquehanna Group Incorporated Llp stated it has 75,619 shs or 0% of all its holdings. Tci Wealth Advisors has 0.01% invested in Cerus Corporation (NASDAQ:CERS). Bb&T Secs Ltd Liability Co invested in 27,400 shs or 0% of the stock. Royal Bank & Trust Of Canada invested 0% in Cerus Corporation (NASDAQ:CERS).

Cerus Corporation had 11 insider sales and 1 insider purchase since March 10, 2018. This’s net activity of $1.32 million. On Saturday, March 10 a trade for 4,610 shs valued at $22,793 was made by Menard Chrystal. ANDERSON TIMOTHY B had sold 23,000 shs worth $152,950. The insider Moore Carol sold 60,841 shs worth $380,865. 52,500 shs were sold by SCHULZE GAIL, worth $349,125. On Monday, March 12 $773,199 worth of stock was bought by CORASH LAURENCE M. Shares for $23,409 were sold by Green Kevin Dennis on Saturday, March 10.

Cerus Corporation (NASDAQ:CERS) Ratings Coverage

In total 2 analysts cover Cerus Corp (NASDAQ:CERS). “Buy” rating has 2, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 4 are the (NASDAQ:CERS)’s analyst reports since January 8, 2018 according to StockzIntelligence Inc. The stock rating was maintained by Cantor Fitzgerald with “Buy” on Tuesday, May 8. On Wednesday, January 24 the firm has “Buy” rating given by Robert W. Baird. On Monday, January 8 the rating was maintained by Cantor Fitzgerald with “Buy”. On Thursday, March 8 Cantor Fitzgerald maintained Cerus Corporation (NASDAQ:CERS) with “Buy” rating. Listed here are Cerus Corporation (NASDAQ:CERS) PTs and latest ratings.

08/05/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $7.0000 Maintain
08/03/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $6.0 Maintain
24/01/2018 Broker: Robert W. Baird Rating: Buy New Target: $6.0 Maintain
08/01/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $5.0 Maintain

Ticker’s shares touched $6.65 during the last trading session after 2.21% change.Cerus Corporation has volume of 176,334 shares. Since June 29, 2017 CERS has risen 221.29% and is uptrending. CERS outperformed by 208.72% the S&P500.

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety.The company has $868.12 million market cap. The Company’s INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products.Currently it has negative earnings. The companyÂ’s INTERCEPT Blood Systems for platelets and plasma are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion.

More recent Cerus Corporation (NASDAQ:CERS) news were announced by Benzinga.com, Nasdaq.com and Benzinga.com. The first one has “Benzinga’s Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street” as a title and was announced on June 21, 2018. The next is “Report: Developing Opportunities within Torchmark, Cerus, American Equity Investment Life Holding, Southern Copper …” on June 28, 2018. And last was announced on June 20, 2018, called “28 Stocks Moving In Wednesday’s Pre-Market Session”.

Cerus Corporation (NASDAQ:CERS) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.